Targeted therapy using alpha particles for ovarian cancer treatment
Antibody-based prertargeted alpha particle therapy for ovarian cancer
This study is testing a new way to treat high-grade serous ovarian cancer by using a special type of radiation that targets cancer cells directly, hoping to help patients who haven't had success with other treatments feel better and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Viewpoint Molecular Targeting, INC. NIH-funded |
| Lab location | 1 site (Coralville, UNITED STATES) |
| Project ID | NIH-10821914 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for high-grade serous ovarian carcinoma (HGSOC), which is a common and aggressive form of ovarian cancer. The approach involves using targeted alpha-particle therapy, which aims to deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. By utilizing advanced imaging techniques and specific targeting of tumor markers, this therapy seeks to improve outcomes for patients who have not responded well to existing treatments. The goal is to enhance survival rates and quality of life for those affected by metastatic HGSOC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous ovarian carcinoma, particularly those with metastatic disease who have not responded to standard therapies.
Not a fit: Patients with early-stage ovarian cancer or those who have not been diagnosed with high-grade serous ovarian carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with metastatic ovarian cancer, potentially improving survival rates and reducing recurrence.
How similar studies have performed: Previous research has shown promise with targeted alpha-particle therapies in other cancer types, indicating potential for success in this novel application for ovarian cancer.
Where this research is happening
Coralville, UNITED STATES
- Viewpoint Molecular Targeting, INC. — Coralville, United States (Active)
Researchers
- Principal investigator: Schultz, Michael King — Viewpoint Molecular Targeting, INC.
- Study coordinator: Schultz, Michael King
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.